On May 6, 2024, Novo Nordisk A/S, a leading global healthcare company, announced the purchase of 6,311,250 B shares from Novo Holdings A/S, valued at DKK 5.43 billion. This transaction is a part of Novo Nordisk's 2024 share repurchase program, which is set to reach up to DKK 20 billion over a 12-month period starting February 6, 2024. The shares were bought at a price of DKK 860.02 each, based on the volume weighted average market price from May 2 to May 6, 2024. Prior to this transaction, Novo Holdings A/S held 28.3% of Novo Nordisk's share capital and 77.4% of the votes. Post-transaction, their stake slightly decreased to 28.2% of the capital and 77.3% of the votes. The share repurchase aligns with Novo Holdings A/S's intention to...Show More

On May 6, 2024, Novo Nordisk A/S, a leading global healthcare company, announced the purchase of 6,311,250 B shares from Novo Holdings A/S, valued at DKK 5.43 billion. This transaction is a part of Novo Nordisk's 2024 share repurchase program, which is set to reach up to DKK 20 billion over a 12-month period starting February 6, 2024. The shares were bought at a price of DKK 860.02 each, based on the volume weighted average market price from May 2 to May 6, 2024. Prior to this transaction, Novo Holdings A/S held 28.3% of Novo Nordisk's share capital and 77.4% of the votes. Post-transaction, their stake slightly decreased to 28.2% of the capital and 77.3% of the votes. The share repurchase aligns with Novo Holdings A/S's intention to maintain its ownership at approximately 28% of Novo Nordisk's share capital, as announced on January 31, 2024. Additionally, incentive programs at Novo Nordisk resulted in a net transfer of 93,461 B shares between May 2 and May 6, 2024. Following these transactions, Novo Nordisk holds 10,163,508 B shares as treasury shares, representing 0.2% of the share capital. The total number of A and B shares in the company, including treasury shares, is 4,465,000,000.